Phase I/IIa study of combination chemotherapy with CKD-602 and cisplatin in patients with recurrent epithelial ovarian cancer

Annals of the New York Academy of Sciences

Volumn 1171, Issue , 2009, Pages 627-634

  Kim, Hee Seung ^a   Kang, Sok Bom ^b   Seo, Sang Soo ^b   Han, Seung Su ^c   Kim, Jae Weon ^a   Park, Noh Hyun ^a   Kang, Soon Beom ^a   Lee, Hyo Pyo ^d   Song, Yong Sang ^a  

^a Seoul National University   (South Korea)

^b National Cancer Center   (South Korea)

^c Chung Ang University   (South Korea)

^d Konkuk University Hospital   (South Korea)

Author keywords

Cisplatin; CKD 602; Ovarian cancer; Recurrent

Indexed keywords

BELOTECAN; CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; GEMCITABINE; PACLITAXEL;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; BLEEDING; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DIARRHEA; DISEASE FREE INTERVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FEVER; DRUG RESPONSE; DRUG SENSITIVITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HYPONATREMIA; INFECTION; LEUKOPENIA; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROTEIN BLOOD LEVEL; RECURRENT CANCER; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

EID: 69149089272     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.04885.x     Document Type: Conference Paper

References (21)

1. Jemal, A. et al. 2006. Cancer statistics, 2006. CA Cancer J. Clin. 56 : 106 130.
2. Ozols, R.F. et al. 2003. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21 : 3194 3200.
3. Bookman, M.A. et al. 2003. Optimal therapy of advanced ovarian cancer: cabopltina and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5. J. Gynecol. Cancer 13 : 735 740.
4. Markman, M. et al. 1991. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J. Clin. Oncol. 9 : 389 393.
5. Shapiro, J.D. et al. 1996. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol. Oncol. 63 : 89 93.
6. Muggia, F.M. et al. 1997. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J. Clin. Oncol. 15 : 987 993.
7. Hoskins, P.J. K.D. Swenerton. 1994. Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J. Clin. Oncol. 12 : 60 63.
8. Hoskins, P. et al. 1998. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J. Clin. Oncol. 16 : 2233 2237.
9. Crul, M. 2003. CKD-602. Chong Kun Dang. Curr. Opin. Investig. Drugs 4 : 1455 1459.
10. Lee, J.H. et al. 2000. Preclinical and phase I clinical studies with Ckd-602, a novel camptothecin derivative. Ann. N.Y. Acad. Sci. 922 : 324 325.
11. Park, I.S. et al. 2002. In vitro pharmacodynamics of CKD-602 in HT-29 cells. Arch. Pharm. Res. 25 : 718 723.
12. Rustin, G.J. et al. 1996. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J. Clin. Oncol. 14 : 1545 1551.
13. Bookman, M.A. et al. 1998. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J. Clin. Oncol. 16 : 3345 3352.
14. Kudelka, A.P. et al. 1996. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J. Clin. Oncol. 14 : 1552 1557.
15. Markman, M. et al. 2000. Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer. Gynecol. Oncol. 79 : 116 119.
16. Swisher, E.M. et al. 1997. Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynecol. Oncol. 66 : 480 486.
17. Bhoola, S.M. et al. 2004. Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer. Gynecol. Oncol. 95 : 564 569.
18. Creemers, G.J. et al. 1996. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J. Clin. Oncol. 14 : 3056 3061.
19. Ghamande, S.A. M.S. Piver. 1999. Role of salvage chemotherapy with topotecan and cisplatin in patients with paclitaxel- and platinum-resistant recurrent ovarian or primary peritoneal cancer: a phase II pilot study. J. Surg. Oncol. 72 : 162 166.
20. Rose, P.G. et al. 2005. A phase I/II trial of weekly topotecan and carboplatin in potentially platinum-sensitive relapsed ovarian and peritoneal carcinoma. Gynecol. Oncol. 99 : 714 719.
21. Bolis, G. et al. 2001. A phase I/II study of topotecan in combination with carboplatin in recurrent epithelial ovarian cancer. Gynecol. Oncol. 83 : 477 480.